Document Detail


Licorice: a sweet alternative to prevent hyperkalemia in dialysis patients?
MedLine Citation:
PMID:  19789539     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In patients on hemodialysis, Farese et al. report that inhibition of the enzyme 11beta-hydroxysteroid dehydrogenase type 2 by glycyrrhetinic acid, the active compound of licorice, reduces serum potassium concentration and the frequency of hyperkalemia, possibly by enhancing intestinal potassium loss. This finding could be an important tool to maintain predialysis [K(+)] within safe limits in some dialysis patients at risk of hyperkalemic arrhythmias.
Authors:
Paolo Ferrari
Related Documents :
10277069 - Avoiding evaluation cooptation. lessons from a renal dialysis evaluation.
8604709 - Electron beam computed tomography in the evaluation of cardiac calcification in chronic...
16207659 - Levocarnitine and dialysis: a review.
19889239 - Lack of association between mutations of gene-encoding mitochondrial d310 (displacement...
20370459 - When is dialysis indicated in acute kidney injury?
21316049 - The role of intraductal us in the management of idiopathic recurrent pancreatitis witho...
12479729 - Bilateral vocal fold paresis and multiple system atrophy.
24039869 - Pentraxin-3 serum levels are associated with disease severity and mortality in patients...
6229179 - Fc-specific reticulo-endothelial clearance in systemic lupus erythematosus and glomerul...
Publication Detail:
Type:  Comment; Journal Article    
Journal Detail:
Title:  Kidney international     Volume:  76     ISSN:  1523-1755     ISO Abbreviation:  Kidney Int.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-09-30     Completed Date:  2009-12-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0323470     Medline TA:  Kidney Int     Country:  United States    
Other Details:
Languages:  eng     Pagination:  811-2     Citation Subset:  IM    
Affiliation:
Department of Nephrology, Fremantle Hospital, University of Western Australia, Perth, Australia. paolo.ferrari@health.wa.gov.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
11-beta-Hydroxysteroid Dehydrogenase Type 2 / antagonists & inhibitors*,  metabolism
Arrhythmias, Cardiac / etiology,  prevention & control
Biological Markers / blood
Cortisone / blood
Enzyme Inhibitors / administration & dosage*,  adverse effects
Food, Fortified*
Glycyrrhetinic Acid / administration & dosage*,  adverse effects
Glycyrrhiza*
Humans
Hydrocortisone / blood
Hyperkalemia / blood,  etiology,  physiopathology,  therapy*
Kidney Failure, Chronic / blood,  physiopathology,  therapy*
Potassium / blood,  urine
Renal Dialysis / adverse effects*
Time Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Enzyme Inhibitors; 471-53-4/Glycyrrhetinic Acid; 50-23-7/Hydrocortisone; 53-06-5/Cortisone; 7440-09-7/Potassium; EC 1.1.1.146/11-beta-Hydroxysteroid Dehydrogenase Type 2; EC 1.1.1.146/HSD11B2 protein, human
Comments/Corrections
Comment On:
Kidney Int. 2009 Oct;76(8):877-84   [PMID:  19641483 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Salivary analysis of oral cancer biomarkers.
Next Document:  Uremic memory: the role of acute kidney injury in long-term outcomes.